89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality OfficerGlobeNewsWire • Monday
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASHInvestors Business Daily • 06/05/24
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver CongressGlobeNewsWire • 05/22/24
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisGlobeNewsWire • 05/14/24
89bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/24
89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASHGlobeNewsWire • 05/02/24
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsGlobeNewsWire • 04/17/24
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated CirrhosisGlobeNewsWire • 03/27/24
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with FibrosisGlobeNewsWire • 03/12/24
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to TradeZacks Investment Research • 03/05/24
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease TreatmentInvestors Business Daily • 03/04/24
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 02/29/24
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24